Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 4/20 | 0.50 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.50 |
| ▸ | YAP1 | P46937 | 1/20 | 0.45 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.45 |
| ▸ | MITF | O75030 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | XBP1 | P17861 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | USP19 | O94966 | 4/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6984335 | 0.87 | DPP4 (0.47) | DPP4DPP7YAP1TEAD4 | |
| SCHEMBL18284789 | 0.86 | MEN1 (0.52) | DPP4DPP7KMT2AHTTUSP19 | |
| SCHEMBL7749807 | 0.83 | RIPK1 (0.46) | DPP4DPP7USP19RIPK1MAPK1 | |
| SCHEMBL20528485 | 0.83 | DPP4 (0.46) | DPP4DPP7KMT2AHPGDSMN1; SMN2 | |
| SCHEMBL2935422 | 0.83 | DPP4 (0.46) | DPP4DPP7KMT2AHPGDSMN1; SMN2 | |
| SCHEMBL21801033 | 0.83 | DPP4 (0.46) | DPP4DPP7KMT2AHPGDSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL9258072 | 0.82 | DPP4 (0.46) | DPP4DPP7KMT2AHPGDSMN1; SMN2 | |
| SCHEMBL2386164 | 0.81 | DPP4 (0.47) | DPP4DPP7USP19RIPK1MAPK1 | |
| SCHEMBL1580100 | 0.81 | POLB (0.54) | DPP4DPP7KMT2AHTTUSP19 | |
| SCHEMBL8496002 | 0.81 | DPP4 (0.45) | DPP4DPP7KMT2AHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324216-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100240618-A1 | SUBSTITUTED PIPERAZINES | CHEMOCENTRYX, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-7589199-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2009-09-15 | — | — | US | disclosed |
| US-20060106218-A1 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2006-05-18 | — | — | US | disclosed |
| US-20050256130-A1 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2005-11-17 | — | — | US | disclosed |
| EP-0077720-A1 | Biphenyl alkyl carboxylated derivatives, process for their preparation and their use as medicines | PIERRE FABRE S.A. (FR) | 1983-04-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106218-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | DPP4 2464/4885DPP7 1494/4885YAP1 3846/4885 |
| US-20050256130-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | DPP4 2464/4885DPP7 1494/4885YAP1 3846/4885 |
| US-20100240618-A1 | SUBSTITUTED PIPERAZINES | CCR1, CCR3, CCRL2 | DPP4 2464/4885DPP7 1494/4885YAP1 3846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.